ARTHQ (Arch Therapeutics) E10: $-6.97 (As of Jun. 2024)


ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics E10?

Arch Therapeutics ARTHQ -99.00% 12 E10 is $-6.97 as of Jun. 2024. GuruFocus rates ARTHQ with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Arch Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2024 was $-1.440. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-6.97 for the trailing ten years ended in Jun. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-25), Arch Therapeutics's current stock price is $0.0001. Arch Therapeutics's E10 for the quarter that ended in Jun. 2024 was $-6.97. Arch Therapeutics's Shiller PE Ratio of today is .


Arch Therapeutics  (OTCPK:ARTHQ) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Arch Therapeutics E10 Related Terms


Arch Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics E10 Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -12.93 -12.87 -9.80

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.09 -9.80 -9.56 -6.51 -6.97

ARTHQ vs GRTSQ, MTEM, PXMD: E10 Comparison

For the Biotechnology subindustry, Arch Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's Shiller PE Ratio falls into.


ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arch Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-1.44/314.1750*314.1750
=-1.440

Current CPI (Jun. 2024) = 314.1750.

Arch Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201409 2.000 238.031 2.640
201412 2.000 234.812 2.676
201503 -2.000 236.119 -2.661
201506 -2.000 238.638 -2.633
201509 -4.000 237.945 -5.281
201512 -2.000 236.525 -2.657
201603 -2.000 238.132 -2.639
201606 -2.000 241.018 -2.607
201609 -2.000 241.428 -2.603
201612 -2.000 241.432 -2.603
201703 -2.000 243.801 -2.577
201706 -2.000 244.955 -2.565
201709 -2.000 246.819 -2.546
201712 0.476 246.524 0.607
201803 -2.000 249.554 -2.518
201806 -2.000 251.989 -2.494
201809 -2.000 252.439 -2.489
201812 -4.000 251.233 -5.002
201903 0.202 254.202 0.250
201906 -2.000 256.143 -2.453
201909 -2.000 256.759 -2.447
201912 -2.000 256.974 -2.445
202003 -0.783 258.115 -0.953
202006 -0.960 257.797 -1.170
202009 0.000 260.280 0.000
202012 -2.000 260.474 -2.412
202103 -2.000 264.877 -2.372
202106 -2.000 271.696 -2.313
202109 -2.000 274.310 -2.291
202112 -1.310 278.802 -1.476
202203 -0.670 287.504 -0.732
202206 -0.880 296.311 -0.933
202209 -1.540 296.808 -1.630
202212 -1.440 296.797 -1.524
202303 -0.710 301.836 -0.739
202306 -1.420 305.109 -1.462
202309 -0.524 307.789 -0.535
202312 -0.570 306.746 -0.584
202403 -0.330 312.332 -0.332
202406 -1.440 314.175 -1.440

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-6.97 mean?
Arch Therapeutics (ARTHQ) has a E10 of $-6.97 as of Jun. 2024. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Arch Therapeutics and its competitors.
Is Arch Therapeutics' E10 too high?
Arch Therapeutics' current E10 is $-6.97. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' E10 compare to GRTSQ and MTEM?
Arch Therapeutics' E10 of $-6.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Arch Therapeutics and its competitors. Arch Therapeutics's current E10 is $-6.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current E10 of $-6.97. The current E10 is $-6.97. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current E10 is $-6.97 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price